23 Jun 2014, BioSpectrum Bureau , BioSpectrum
Singapore: China's research and development service firm, WuXi PharmaTech has cleared the surveillance Good Laboratory Practice (GLP) inspection by US Food and Drug Administration (FDA) for its toxicology facility in Suzhou.
The company mentions this to be the first FDA GLP inspection in facility's five years of operation and the inspection lasted for five days.
WuXi's toxicology facility in Suzhou has completed 92 IND-enabling programs for global submissions.
"The outcome of the FDA inspection further demonstrates the consistency of our GLP compliance and quality services following the excellent results of earlier OECD and CFDA inspections," said Dr Ge Li, Chairman and CEO of WuXi PharmaTech.